City of Hope Medical Center clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
82 trials changed in the last 30 days: 2 stopped, 48 with notable changes, 32 with minor changes only.
- Notable: Pembrolizumab and Blinatumomab · Recurrent or Refractory Acute Lymphoblastic Leukemia Results posted: Nov 17, 2026
- Notable: Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant · High-Risk Acute Leukemia or Myelodysplastic Syndrome Trial status changed: Suspended → Active, Not Recruiting
- Notable: Genetically Engineered Cells (BAFFR-CAR T Cells) · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Recruitment opened
- Minor: Lysozyme Goat Milk · Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant Study completion pushed from Oct 27, 2026 to Mar 23, 2027
- Minor: HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics Study completion pushed from Oct 1, 2026 to Jan 1, 2027
- Notable: Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy Primary and study completion pushed from Nov 25, 2026 to Nov 25, 2027
- Notable: Enasidenib (AG-221) Maintenance Post Allogeneic HCT · IDH2 Mutation Trial status changed: Suspended → Active, Not Recruiting
- Notable: CS1-CAR T Therapy Following Chemotherapy · Relapsed or Refractory CS1 Positive Multiple Myeloma Trial status changed: Suspended → Active, Not Recruiting
- Notable: Intraoperative Neuromonitoring of Sacral Reflexes to Predict Post Operative Function in Patients Undergoing Sacrectomy for Pelvic Bone Malignancy or Patients Undergoing Spinal Procedures Without Sacral Root Involvement Recruitment opened
- Minor: Leflunomide, Pomalidomide, and Dexamethasone · Relapsed or Refractory Multiple Myeloma Enrollment closed, study ongoing
- Minor: Pevonedistat and Ibrutinib · Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Trial completed
- Minor: Gemcitabine and Leflunomide · Advanced Unresectable Pancreatic Cancer Enrollment closed, study ongoing
- Notable: Stereotactic Body Radiation Therapy and FES PET/CT Imaging · Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer Primary and study completion pushed from Oct 29, 2026 to Oct 29, 2027
- Notable: Leflunomide · High-Risk Smoldering Multiple Myeloma Primary and study completion pushed from Nov 10, 2026 to Oct 13, 2027
- Notable: CD33-CAR T Cell Therapy · Recurrent or Refractory Acute Myeloid Leukemia Primary and study completion pushed from Sep 3, 2028 to Sep 3, 2031
- Notable: Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil · Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Primary and study completion pushed from May 25, 2027 to Nov 5, 2028
- Notable: PSCA-Targeting CAR-T Cells Plus or Minus Radiation · PSCA+ Metastatic Castration-Resistant Prostate Cancer Primary and study completion pushed from Nov 11, 2028 to Nov 11, 2029
- Notable: Ruxolitinib in Combination With CHOP Chemotherapy · Untreated Nodal T-Follicular Helper Cell Lymphomas Primary and study completion pushed from Mar 31, 2027 to Dec 10, 2027
- Minor: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel · Relapsed Multiple Myeloma Enrollment closed, study ongoing
- Minor: Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC Enrollment closed, study ongoing
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-09 | NCT07926893 Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides… | Phase 1 | Not Yet Recruiting |
| 2026-11-09 | NCT07926906 Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and… | Not Yet Recruiting | |
| 2026-11-03 | NCT07914166 Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia… | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 11 | |
| Phase 1 | 109 | |
| Phase 1/2 | 15 | |
| Phase 2 | 86 | |
| Phase 3 | 5 | |
| Phase 4 | 1 |
Not charted: 108 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 45
Leukemia (60) · Non-Hodgkin Lymphoma (49) · Breast Cancer (42) · Acute Myeloid Leukemia (AML) (35) · Acute Lymphoblastic Leukemia (ALL) (34) · Colorectal Cancer (33) · Myelodysplastic Syndromes (MDS) (22) · Prostate Cancer (22) · Lung Cancer (21) · Chronic Lymphocytic Leukemia (CLL) (20)
Get alerts when City of Hope Medical Center's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.